Intrinsiqs

Is Vertex Pharmaceuticals Incorporated overvalued?

Vertex Pharmaceuticals Incorporated (VRTX) looks overvalued — trading about 30% above its fair value.

Overvalued
Current price $525.73 Fair value $370.17
Price
$525.73
Fair value
$370.17
Current P/E
34.3
Normal P/E
24.2
Market cap
$133.43B
Dividend yield
0.0%
Return on equity
23.3%
Sector
Healthcare

See the full interactive analysis →

Fair value compares VRTX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.UNH UnitedHealth Group IncorporatedRHHBY Roche Holding AGMRK Merck & Co., Inc.